Silver Book Fact

A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.

PhRMA Japan. Aricept Reduces Annual Treatment Cost by $1,000 Per Patient: Pfizer; 10-Sep-2000

Reference

Title
Aricept Reduces Annual Treatment Cost by $1,000 Per Patient: Pfizer
Publication Date
10-Sep-2000
Authors
PhRMA Japan

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.  
  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.